Product Description: Contezolid (MRX-I), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid (MRX-I) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI)[1][2].
Applications: COVID-19-immunoregulation
Formula: C18H15F3N4O4
References: [1]Junzhen Wu, et al. Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers. Antimicrob Agents Chemother. 2020 May 21;64(6):e02158-19./[2]Mikhail F Gordeev, et al. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem. 2014 Jun 12;57(11):4487-97./[3]Carolyn Shoen, et al. In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00493-18.
CAS Number: 1112968-42-9
Molecular Weight: 408.33
Compound Purity: 99.37
Research Area: Infection; Inflammation/Immunology
Solubility: DMSO : 120 mg/mL (ultrasonic)
Target: Antibiotic;Bacterial;Monoamine Oxidase
Deutsch
English
